Entellus ultra balloon system5/16/2023 ![]() ![]() Forward-looking statements in this release include the anticipated benefits of Entellus’s balloon sinus dilation products and the momentum of its business. Forward-looking statements generally can be identified by the use of words such as “intend,” “expect,” “anticipate,” “could,” “may,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Entellus is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.Īll statements contained in this release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Entellus’s product lines including the XprESS™ ENT Dilation System, Latera™ Absorbable Nasal Implant, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the most cost effective and efficient site of care. The Entellus platform of products provides safe, effective and easy-to-use solutions intended to enable treatment of patients in more cost-effective sites of care. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, patients with nasal airway obstruction, as well as adult patients with persistent Eustachian tube dysfunction. This policy change further underscores clinician and payer confidence in the safety and efficacy of BSD as established by a significant body of clinical evidence, and in the value of this technology intended to enable better patient outcomes in more cost-effective sites of care.Įntellus is a medical technology company focused on delivering superior patient and physician experiences through products designed for less invasive treatments. ![]() With the Anthem policy change, approximately 95% of insured patients in the United States now have access to balloon dilation of the sinuses as covered treatment option when appropriate. “We have considerable momentum driven by our broad portfolio and pipeline, clinical programs, and expanded reimbursement to improve patients’ lives.” “The recent positive coverage decision by Anthem brings total covered lives for BSD in the United States to over 290 million, enabling broad availability of cost effective solutions for the treatment of chronic sinusitis with our XprESS system,” said Robert White, President and Chief Executive Officer of Entellus Medical. The overall criteria for coverage closely aligns with the recently developed clinical consensus statement soon to be published by the American Academy of Otolaryngology – Head and Neck Surgeons (AAO-HNS) on balloon dilation of sinuses. This includes patients with documented evidence of sinus disease upon physician examination, via nasal endoscopy, or on a computer tomographic (CT) scan. This new policy extends coverage to patients with both chronic and recurrent acute sinusitis. Anthem, the largest member of the Blue Cross Blue Shield Association, is the nation’s second largest health benefits company with plans that cover over 40 million lives, or 12.5% of the population of the United States. now covers balloon sinus dilation (BSD) for the treatment of chronic and recurrent acute sinusitis. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that Anthem, Inc. ![]() 13, 2017 (GLOBE NEWSWIRE) - Entellus Medical, Inc. ![]()
0 Comments
Leave a Reply. |